多西他赛单药化疗与联合铂类一线治疗老年晚期非小细胞肺癌的有效性与安全性研究

Effective and safety study of docetaxel single agent chemotherapy and combined with platinum based first-line in the treatment of elderly patients with advanced non small cell lung cancer

目的:探讨多西他赛联合顺铂与单药多西他赛治疗老年晚期非小细胞肺癌的有效性与安全性。方法:2012-2013年收治晚期非小细胞肺癌老年患者90例,按照随机数字表法将患者分为观察组及对照组,各45例,比较两组患者的近期疗效,同时对两组患者的用药安全性进行评价。结果:两组近期疗效比较差异无统计学意义(P>0.05);观察组骨髓移植、消化道反应发生率高于对照组,比较差异有统计学意义(P<0.05)。结论:多西他赛联合顺铂与单药多西他赛治疗老年晚期非小细胞肺癌,疗效差异不大,但联合用药化疗不良反应明显增加,在一定程度上多西他赛单药化疗更适合老年晚期非小细胞肺癌的治疗。

Objective:To investigate the efficacy and safety of docetaxel combined with cisplatin and single docetaxel in treatment of elderly patients with advanced non small cell lung cancer.Methods:90 aged patients with advanced non small cell lung cancer were selected from 2012 to 2013.They were divided into the observation group and the control group with 45 cases in each group according to the random number table method.We compared the curative effect in the near future of the two groups patients,and evaluated the drug use safety of two groups patients.Results:The comparison of short-term effect of the observation group patients had no difference,and there were no statistical significance(P＞0.05);the observation group patients with bone marrow transplantation,digestive tract reaction rate were higher than those of the control group,and the difference was statistically significant(P＜0.05).Conclusion:The combination of docetaxel and cisplatin and docetaxel in the treatment of elderly patients with advanced non small cell lung cancer,the curative effect difference is not big,but the side effects of drug combination chemotherapy increased significantly in a certain extent,docetaxel single agent chemotherapy is more suitable for elderly patients with advanced non small cell lung cancer.